The FDA Group
The FDA Group: Expert FDA Regulatory Consulting for Medical Devices
The FDA Group is a premier FDA regulatory consulting firm dedicated to empowering medical device companies. With seasoned experts, they specialize in strategic planning and execution for 510(k) submissions, de novo applications, and PMA processes across various device classes and panels. They provide tailored solutions accelerating product development and ensuring compliance through comprehensive support from initial classification assessments and QMS implementation to post-market vigilance and international regulatory strategies.
About
The FDA Group is a premier FDA regulatory consulting firm dedicated to empowering medical device companies. With seasoned experts, they specialize in strategic planning and execution for 510(k) submissions, de novo applications, and PMA processes across various device classes and panels. They provide tailored solutions accelerating product development and ensuring compliance through comprehensive support from initial classification assessments and QMS implementation to post-market vigilance and international regulatory strategies.
Additional information
### **Additional information**
- **Type:** firm
- **Company:** The FDA Group
- **Years of experience:** 7
- **510(k)s submitted (self-reported):** 15
- **Regions served:** US, EU
- **Client types:** startup, sme, large_medtech
- **Location:** US
- **Availability:** available_now
### **Cruxi analysis**
- **Strength summary:** The FDA Group stands out as a premier FDA regulatory consulting firm with a robust team of seasoned experts, offering unparalleled depth in navigating complex medical device regulatory pathways. Their comprehensive expertise spans 510(k) submissions (traditional and special), de novo applications, and PMA processes across all device classes (I, II, and III) and a broad spectrum of device panels including ophthalmic, cardiovascular, and neurology. The firm demonstrates a strong technical competency with explicit services for Software as a Medical Device (SaMD), AI/ML, implantables, and IVD tests, further supported by their proficiency in Quality Management Systems (QMS) and international regulatory strategies for US and EU markets. With a clear commitment to accelerating product development and ensuring compliance, The FDA Group's extensive service offering, from initial pathway assessment and predicate analysis to full submission authoring and post-market vigilance, positions them as an indispensable strategic partner for medtech companies of all sizes, from startups to large enterprises.
- **Unique value:** The FDA Group distinguishes itself through its deep bench of experienced regulatory professionals and its comprehensive, end-to-end service model that uniquely bridges strategic planning with rigorous execution for a wide array of medical device types and regulatory pathways. Their ability to manage diverse submissions across all device classes and panels, coupled with specialized technical competencies in areas like SaMD and AI/ML, ensures tailored, effective solutions that accelerate market access.
- **Ideal projects:** The ideal client for The FDA Group is a medical device company, regardless of size (startup, SME, or large medtech), seeking expert guidance and execution for complex regulatory submissions, particularly within the US and EU markets. This includes companies developing devices across Class I, II, and III, especially those involving ophthalmic, cardiovascular, neurological, or IVD technologies, and those leveraging advanced technologies like SaMD or AI/ML. Engagement is most beneficial when companies require strategic planning for 510(k), de novo, or PMA pathways, need to establish or improve their QMS, or are navigating international market access. Companies proactively seeking to optimize their regulatory strategy and accelerate time-to-market would find exceptional value in partnering with The FDA Group.
- **Confidence score:** 80/100
- **Last analyzed:** Sat Dec 20 2025 01:45:07 GMT-0500 (Eastern Standard Time)
### **Qualifications & scope**
- **Submission types:** 510k-traditional, 510k-special, de-novo, pma, qms, international
- **Device classes:** class-i, class-ii, class-iii
- **Specialties:** ophthalmic, regulatory strategy, quality management systems, risk management, preclinical testing
- **Device panels:** ophthalmic, general_surgery, ivd, radiology, dental, cardiovascular, neurology, orthopedic, other
- **Regulatory pathways:** 510k, de_novo, pma, ide, q_sub, post_market
- **Type:** firm
- **Company:** The FDA Group
- **Years of experience:** 7
- **510(k)s submitted (self-reported):** 15
- **Regions served:** US, EU
- **Client types:** startup, sme, large_medtech
- **Location:** US
- **Availability:** available_now
### **Cruxi analysis**
- **Strength summary:** The FDA Group stands out as a premier FDA regulatory consulting firm with a robust team of seasoned experts, offering unparalleled depth in navigating complex medical device regulatory pathways. Their comprehensive expertise spans 510(k) submissions (traditional and special), de novo applications, and PMA processes across all device classes (I, II, and III) and a broad spectrum of device panels including ophthalmic, cardiovascular, and neurology. The firm demonstrates a strong technical competency with explicit services for Software as a Medical Device (SaMD), AI/ML, implantables, and IVD tests, further supported by their proficiency in Quality Management Systems (QMS) and international regulatory strategies for US and EU markets. With a clear commitment to accelerating product development and ensuring compliance, The FDA Group's extensive service offering, from initial pathway assessment and predicate analysis to full submission authoring and post-market vigilance, positions them as an indispensable strategic partner for medtech companies of all sizes, from startups to large enterprises.
- **Unique value:** The FDA Group distinguishes itself through its deep bench of experienced regulatory professionals and its comprehensive, end-to-end service model that uniquely bridges strategic planning with rigorous execution for a wide array of medical device types and regulatory pathways. Their ability to manage diverse submissions across all device classes and panels, coupled with specialized technical competencies in areas like SaMD and AI/ML, ensures tailored, effective solutions that accelerate market access.
- **Ideal projects:** The ideal client for The FDA Group is a medical device company, regardless of size (startup, SME, or large medtech), seeking expert guidance and execution for complex regulatory submissions, particularly within the US and EU markets. This includes companies developing devices across Class I, II, and III, especially those involving ophthalmic, cardiovascular, neurological, or IVD technologies, and those leveraging advanced technologies like SaMD or AI/ML. Engagement is most beneficial when companies require strategic planning for 510(k), de novo, or PMA pathways, need to establish or improve their QMS, or are navigating international market access. Companies proactively seeking to optimize their regulatory strategy and accelerate time-to-market would find exceptional value in partnering with The FDA Group.
- **Confidence score:** 80/100
- **Last analyzed:** Sat Dec 20 2025 01:45:07 GMT-0500 (Eastern Standard Time)
### **Qualifications & scope**
- **Submission types:** 510k-traditional, 510k-special, de-novo, pma, qms, international
- **Device classes:** class-i, class-ii, class-iii
- **Specialties:** ophthalmic, regulatory strategy, quality management systems, risk management, preclinical testing
- **Device panels:** ophthalmic, general_surgery, ivd, radiology, dental, cardiovascular, neurology, orthopedic, other
- **Regulatory pathways:** 510k, de_novo, pma, ide, q_sub, post_market
Key Highlights
- The FDA Group stands out as a premier FDA regulatory consulting firm with a robust team of seasoned experts, offering unparalleled depth in navigating complex medical device regulatory pathways. Their comprehensive expertise spans 510(k) submissions (traditional and special), de novo applications, and PMA processes across all device classes (I, II, and III) and a broad spectrum of device panels including ophthalmic, cardiovascular, and neurology. The firm demonstrates a strong technical competen
- The FDA Group distinguishes itself through its deep bench of experienced regulatory professionals and its comprehensive, end-to-end service model that uniquely bridges strategic planning with rigorous execution for a wide array of medical device types and regulatory pathways. Their ability to manage diverse submissions across all device classes and panels, coupled with specialized technical competencies in areas like SaMD and AI/ML, ensures tailored, effective solutions that accelerate market ac
Certifications & Trust Signals
- 7 years experience
- 15 510(k)s submitted (self-reported)
Buyer Snapshot
Best for
- The ideal client for The FDA Group is a medical device company, regardless of size (startup, SME, or large medtech), seeking expert guidance and execution for complex regulatory submissions, particularly within the US and EU markets. This includes companies developing devices across Class I, II, and III, especially those involving ophthalmic, cardiovascular, neurological, or IVD technologies, and
HQ:
US
Languages:
English
Timezones:
EST
Claim status:
Listed
Services & Capabilities
FDA 510(k) Submission Services
Services Offered:
510(k) Strategy & Authoring, 510(k) eSTAR Preparation, Pre-Sub / Q-Sub Preparation, FDA Meeting Support (Q-Sub / Type C), Labeling Review for Submission (510(k)/De Novo/PMA), Submission Project Management (end-to-end), 510(k) RTA Remediation / Refuse-to-Accept Fix, Predicate Research & Substantial Equivalence Strategy, Regulatory Pathway Assessment, PMA Strategy & Support, De Novo Strategy & Authoring
Pathways Supported:
Traditional 510(k), Special 510(k), Abbreviated 510(k), De Novo, PMA, Pre-Sub / Q-Sub
Device Types Supported:
Medical device
Supports Estar:
Yes
Supports Rta Remediation:
Yes
Supports Predicate Research:
Yes
Supports Labeling Review:
Yes
Provides Submission Project Management:
Yes
Ex FDA:
Yes
Engagement Models:
Contracted, Embedded, Fractional executive support, Interim leadership
